Consideration of the several processes involved in sustained attention underscores the need for techniques designed to separate the components. This study_employed two parameters from signal detection theory, perceptual sensitivity [P(A)] and decision criterion cutoff scores [Z(S/M)]> in the analysis of vigilance performance of hyperactive (« = 30), hypoxic (n = 30), and normal (n = 47) children Signal detection analyses of three Continuous Performance Test conditions indicated that, with increasing age, children obtained significantly more hits, fewer false alarms, higher perceptual sensitivity, and responded with greater caution Overall deficits in signal discrimination (perceptual sensitivity level) were obtained for both the hyperactive and the hypoxic groups when compared to normal age mates Whereas the hypoxic group demonstrated additional decrements in sustaining attention (sensitivity decrement over time), the hyperactive children were impaired by lowresponse caution, reflecting difficulty inhibiting impulsive responses Possible differences in hyperactive sample characteristics across studies and time-related recovery factors following hypoxia are discussed
BackgroundSeveral lines of evidence suggest that Herpes Simplex Virus type 1 (HSV-1) may contribute to cognitive impairment in schizophrenia. Herpes viruses are enveloped, double stranded DNA viruses that are capable of infecting human CNS resulting in life-long infection with over 40% of the population seropositive for this virus. Valacyclovir is an effective treatment for the suppression of herpes virus infections. A previous small clinical trial (N=24) assessed the efficacy of valacyclovir for cognitive impairment in patients with early phase schizophrenia who were seropositive for HSV-1 (Prasad et al 2013). Results indicate that adjunctive valacyclovir, as compared to placebo, showed improvement in working and visual memory. The current study was undertaken to confirm and extend these findings and determine if HSV-1 seropositive, as compared to those who were HSV-1 seronegative, derived cognitive improvement from adjunctive valacyclovir. We hypothesized that individuals who were HSV-1 positive, but not HSV-1 negative, would demonstrate significant valacyclovir efficacy for cognitive impairment.MethodsAn early psychosis network comprised of 12 US sites was established for the valacyclovir trial. Subjects had early phase schizophrenia (within 8 years since psychosis onset) and were randomized 1:1 to a 16-week trial of adjunctive valacyclovir (3 grams/day) or placebo. Assessments included cognitive domains (MATRICS), role functioning (UPSA-B, Q-LES-Q-SF, PSP), psychiatric symptoms (PANSS, NSA-16) and a range of inflammatory markers. The primary outcome was change in working (composite score of Spatial Span and Letter Number span) and visual (Brief Visuospatial Memory Test) as measured by the MATRICS.Results170 subjects with early phase schizophrenia were stratified by HSV-1 status and randomized 1:1 to adjunctive valacyclovir or adjunctive placebo. Of those randomized, 74 were HSV-1 seropositive and 96 were seronegative. The valacyclovir vs. placebo groups, respectively, were well matched: age (28.4 vs. 27.5 years), gender (males: 69% vs. 77.9 %), race (white-caucasian: 28.6% vs. 33.7%) and duration of psychosis (3.7 vs. 4.0, years). Baseline working memory scores (Letter-Number Span) were significantly lower in HSV1 positive vs. negative subjects (mean/SD: vs. 35.1/9.0 vs 38.3/11.0, p=0.046). Treatment outcome analyses have only recently commenced and are ongoing. Full results of the cognitive, functioning, symptom and safety measures will be presented at the meeting.DiscussionThe current study included 170 patients with early phase schizophrenia randomized to valacyclovir or placebo and stratified by HSV1 sero-status. Baseline working memory scores (Letter-Number Span) were significantly lower in HSV1 positive compared to HSV1 negative subjects. As analyses of treatment effects are ongoing, detailed results of valacyclovir’s effects on cognitive domains, symptoms, functioning and safety will be presented at the meeting. Additional research is needed to determine the full therapeutic potential of valacy...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.